Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BRIEF-Sanofi and Regeneron announce 18-month results of ODYSSEY long term trial with praluent (alirocumab)

By: Reuters: Company News
* Announced on Sunday the 18-month results of a Phase 3 long term trial with praluent (alirocumab) with Regeneron Pharmaceuticals Inc
Related Stocks:
Banco Santander ADR Regeneron Pharmaceuticals
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.